WO2003075851A3 - Compositions and methods for the treatment of anorectal disorders - Google Patents

Compositions and methods for the treatment of anorectal disorders Download PDF

Info

Publication number
WO2003075851A3
WO2003075851A3 PCT/US2003/007106 US0307106W WO03075851A3 WO 2003075851 A3 WO2003075851 A3 WO 2003075851A3 US 0307106 W US0307106 W US 0307106W WO 03075851 A3 WO03075851 A3 WO 03075851A3
Authority
WO
WIPO (PCT)
Prior art keywords
adrenergic
activators
antagonists
compounds
inhibitors
Prior art date
Application number
PCT/US2003/007106
Other languages
French (fr)
Other versions
WO2003075851A2 (en
Inventor
Thomas P Parks
Vivien H W Mak
Jung-Chung Lee
Charles Lee
Stephen Grayson
Original Assignee
Cellegy Pharma Inc
Thomas P Parks
Vivien H W Mak
Jung-Chung Lee
Charles Lee
Stephen Grayson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellegy Pharma Inc, Thomas P Parks, Vivien H W Mak, Jung-Chung Lee, Charles Lee, Stephen Grayson filed Critical Cellegy Pharma Inc
Priority to AU2003213787A priority Critical patent/AU2003213787A1/en
Publication of WO2003075851A2 publication Critical patent/WO2003075851A2/en
Publication of WO2003075851A3 publication Critical patent/WO2003075851A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients

Abstract

Compositions and methods for the treatment of patients with anorectal disorders including colostomy are provided in which certain compounds including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators (including acetylcholine storage blocking agents and acetylcholine vesicle storage blocking agents), α-adrenergic receptor antagonists (including α1-adrenergic antagonists and α2-adrenergic antagonists), β-adrenergic receptor agonists (including β2-adrenergic antagonists and β3-adrenergic antagonists), phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g., cAMP mimetics), superoxide scavengers, potassium channel activators (including ATP-sensitive potassium channel activators and activators of the Maxi-K channels), estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators, endothelin receptor antagonists, bisphosphonates, cGMP-dependent protein kinase activators (e.g., cGMP mimetics), and combinations thereof are used.
PCT/US2003/007106 2002-03-06 2003-03-05 Compositions and methods for the treatment of anorectal disorders WO2003075851A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003213787A AU2003213787A1 (en) 2002-03-06 2003-03-05 Compositions and methods for the treatment of anorectal disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36269802P 2002-03-06 2002-03-06
US60/362,698 2002-03-06

Publications (2)

Publication Number Publication Date
WO2003075851A2 WO2003075851A2 (en) 2003-09-18
WO2003075851A3 true WO2003075851A3 (en) 2009-06-18

Family

ID=27805213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007106 WO2003075851A2 (en) 2002-03-06 2003-03-05 Compositions and methods for the treatment of anorectal disorders

Country Status (2)

Country Link
AU (1) AU2003213787A1 (en)
WO (1) WO2003075851A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
MXPA05004278A (en) 2002-10-25 2005-10-05 Foamix Ltd Cosmetic and pharmaceutical foam.
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
PL3261645T3 (en) 2015-02-27 2021-12-06 Dechra Limited Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11197848B2 (en) 2018-06-01 2021-12-14 Tavanta Therapeutics Hungary Incorporated Topical amlodipine salts for the treatment of anorectal diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035434A2 (en) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035434A2 (en) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions

Also Published As

Publication number Publication date
AU2003213787A1 (en) 2003-09-22
WO2003075851A2 (en) 2003-09-18
AU2003213787A8 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
WO2003075851A3 (en) Compositions and methods for the treatment of anorectal disorders
BR9916162A (en) Composition and method for the treatment of an anorectal disorder and for controlling the pain associated with it
WO1999010338A3 (en) Benzylidene- and cinnamylidene-anabaseines as neuronal nicotinic alpha-7 receptor agonists
WO2000056301A3 (en) Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
WO2004052348A3 (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
ZA200500951B (en) Azabicyclo derivatives as muscarinic receptor antagonists
BRPI0610876B8 (en) compound, pharmaceutical formulation, and methods of inhibiting an activity of a jak kinase, and of inhibiting a signal transduction cascade in which jak3 kinase plays a role
PL409305A1 (en) 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile and the pharmaceutical composition and their use
EP1369129A4 (en) Remedies for depression containing ep1 antagonist as the active ingredient
YU33802A (en) Polycycloalkylpurines as adenosine receptor antagonists
EP1990338A3 (en) Biphenylcyclopropylamides as p-38 Kinase inhibitors
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
HK1077193A1 (en) Alpha-7 nicotinic receptor agonists and statins incombination
MY145332A (en) Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA06010904A (en) Tricyclic pyrazole kinase inhibitors.
WO2007044441A3 (en) Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
HK1064948A1 (en) Use of an adenosine a3 receptor agonist for inhibition of viral replication
WO2006060127A3 (en) COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
IL174762A0 (en) Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
MXPA03003482A (en) Treatment of sexual dysfunction.
WO2004103288A3 (en) Method of preventing recurrent miscarriages
WO2004041755A3 (en) Quinazolinone compounds as calcilytics
YU33702A (en) Adenosine receptor antagonists and methods of making and using the same
CR20230306A (en) Novel compounds as androgen receptor and phosphodiesterase dual inhibitor
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP